Tendering and value-based pricing: lessons from Italy on human papilloma virus vaccines.
作者信息
Garattini Livio, Van de Vooren Katelijne, Freemantle Nick
机构信息
Center for Health Economics, IRCCS Institute for Pharmacological Research 'Mario Negri', Ranica 24020, Italy.
出版信息
J R Soc Med. 2014 Jan;107(1):4-5. doi: 10.1177/0141076813512122.
Abstract
摘要
相似文献
1
Tendering and value-based pricing: lessons from Italy on human papilloma virus vaccines.招标与基于价值的定价：来自意大利的人乳头瘤病毒疫苗经验教训
J R Soc Med. 2014 Jan;107(1):4-5. doi: 10.1177/0141076813512122.
2
Pricing human papillomavirus vaccines: lessons from Italy.人乳头瘤病毒疫苗定价：来自意大利的经验教训
Pharmacoeconomics. 2012 Mar;30(3):213-7. doi: 10.2165/11596560-000000000-00000.
3
Cost-risk analysis of available cervix cancer vaccine: Situation analysis from Thailand.现有宫颈癌疫苗的成本-风险分析：泰国的情况分析
J Cancer Res Ther. 2019 Oct-Dec;15(6):1421. doi: 10.4103/jcrt.JCRT_415_18.
4
HPV vaccine strategies: the cost of HPV and the choice of vaccine.人乳头瘤病毒疫苗策略：人乳头瘤病毒的成本与疫苗选择
Sex Transm Infect. 2009 Sep;85(5):315-6. doi: 10.1136/sti.2008.034793.
5
Do you approve of spending $300 million on HPV vaccination?: no.你赞成花费3亿美元用于人乳头瘤病毒疫苗接种吗？：不赞成。
Can Fam Physician. 2008 Feb;54(2):175, 177, 179, 181.
6
Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.重点介绍四价人乳头瘤病毒（6、11、16、18 型）重组疫苗（佳达修®）在预防女性的癌前生殖器病变、生殖器癌和生殖器疣方面的作用。
BioDrugs. 2011 Oct 1;25(5):339-43. doi: 10.2165/11205060-000000000-00000.
7
Cost-effectiveness of different human papillomavirus vaccines in Singapore.新加坡不同人乳头瘤病毒疫苗的成本效益分析。
BMC Public Health. 2011 Mar 31;11:203. doi: 10.1186/1471-2458-11-203.
8
For debate: that Australia should continue using the quadrivalent vaccine.供讨论：澳大利亚应继续使用四价疫苗。
Sex Health. 2010 Sep;7(3):235-7. doi: 10.1071/sh09129.
9
Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis.中国9价人乳头瘤病毒疫苗预防宫颈癌的成本效益及基于价值的定价：一项经济建模分析
BMJ Open. 2019 Nov 24;9(11):e031186. doi: 10.1136/bmjopen-2019-031186.
10
Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh.孟加拉国为少女接种二价（Cervarix）和四价（Gardasil）HPV 疫苗的成本效益分析。
Vaccine. 2020 Jan 10;38(2):165-172. doi: 10.1016/j.vaccine.2019.10.037. Epub 2019 Oct 24.
引用本文的文献
1
A concept for multi-winner tenders for medicinal products with balancing between efficient prices, long-term competition and sustainability of supply.一种针对药品多赢家招标的概念，兼顾有效价格、长期竞争和供应可持续性。
Front Med (Lausanne). 2023 Oct 30;10:1282698. doi: 10.3389/fmed.2023.1282698. eCollection 2023.
2
Impact of changes in the methodology of external price referencing on medicine prices: discrete-event simulation.外部价格参考方法的变化对药品价格的影响：离散事件模拟
Cost Eff Resour Alloc. 2020 Nov 16;18(1):51. doi: 10.1186/s12962-020-00247-3.
3
Vaccine Prices: A Systematic Review of Literature.疫苗价格：文献系统综述
Vaccines (Basel). 2020 Oct 29;8(4):629. doi: 10.3390/vaccines8040629.
4
Pricing of HPV vaccines in European tender-based settings.HPV 疫苗在欧洲招标环境下的定价。
Eur J Health Econ. 2019 Mar;20(2):271-280. doi: 10.1007/s10198-018-0996-9. Epub 2018 Jul 26.
5
Drug tendering: drug supply and shortage implications for the uptake of biosimilars.药品招标：药品供应及短缺对生物类似药采用的影响
Clinicoecon Outcomes Res. 2017 Sep 29;9:573-584. doi: 10.2147/CEOR.S140063. eCollection 2017.
6
Factors associated with the pricing of childhood vaccines in the U.S. public sector.美国公共部门儿童疫苗定价的相关因素。
Health Econ. 2018 Feb;27(2):252-265. doi: 10.1002/hec.3539. Epub 2017 Jun 29.
7
Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV.两种人乳头瘤病毒疫苗真的相似吗？现有证据的系统评价：两种疫苗对 HPV 的功效。
J Immunol Res. 2015;2015:435141. doi: 10.1155/2015/435141. Epub 2015 Aug 25.
8
Pricing of forthcoming therapies for hepatitis C in Europe: beyond cost-effectiveness?欧洲即将上市的丙型肝炎治疗药物定价：超越成本效益？
Eur J Health Econ. 2015 May;16(4):341-5. doi: 10.1007/s10198-014-0653-x.
本文引用的文献
1
Pricing human papillomavirus vaccines: lessons from Italy.人乳头瘤病毒疫苗定价：来自意大利的经验教训
Pharmacoeconomics. 2012 Mar;30(3):213-7. doi: 10.2165/11596560-000000000-00000.
2
Economic evaluation of human papilloma virus vaccination in the European Union: a critical review.人乳头瘤病毒疫苗接种在欧盟的经济评估：批判性回顾。
Intern Emerg Med. 2011 Apr;6(2):163-74. doi: 10.1007/s11739-011-0529-3. Epub 2011 Feb 11.
3
Cost-effectiveness analyses of vaccination programmes : a focused review of modelling approaches.疫苗接种计划的成本效益分析：建模方法的重点综述
Pharmacoeconomics. 2008;26(3):191-215. doi: 10.2165/00019053-200826030-00004.
4
Value based pricing for NHS drugs: an opportunity not to be missed?英国国家医疗服务体系（NHS）药品的基于价值的定价：一个不容错过的机遇？
BMJ. 2008 Feb 2;336(7638):251-4. doi: 10.1136/bmj.39434.500185.25.
5
Something rotten in the state of clinical and economic evaluations?临床和经济评估领域是否存在一些问题？
Health Econ. 1994 Mar-Apr;3(2):63-7. doi: 10.1002/hec.4730030202.
Zotero 插件